Miv-cel Responses Persist at One Year
Kyverna reported 12-month durability from the 26-patient KYSA-8 registrational study in stiff person syndrome and longer follow-up from seven generalized myasthenia gravis patients. Median timed 25-foot walk improvement in SPS was 49% at Month…
